TG Therapeutics (NASDAQ:TGTX – Get Free Report) and Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, profitability and dividends.
Profitability
This table compares TG Therapeutics and Pliant Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| TG Therapeutics | 11.81% | 18.82% | 7.78% |
| Pliant Therapeutics | N/A | -57.13% | -44.97% |
Risk and Volatility
TG Therapeutics has a beta of 1.89, indicating that its stock price is 89% more volatile than the S&P 500. Comparatively, Pliant Therapeutics has a beta of 1.36, indicating that its stock price is 36% more volatile than the S&P 500.
Valuation & Earnings
This table compares TG Therapeutics and Pliant Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| TG Therapeutics | $616.29 million | 16.06 | $447.18 million | $0.66 | 99.21 |
| Pliant Therapeutics | $1.58 million | 25.31 | -$149.34 million | ($1.45) | -0.44 |
TG Therapeutics has higher revenue and earnings than Pliant Therapeutics. Pliant Therapeutics is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent recommendations for TG Therapeutics and Pliant Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| TG Therapeutics | 1 | 1 | 6 | 1 | 2.78 |
| Pliant Therapeutics | 1 | 1 | 1 | 0 | 2.00 |
TG Therapeutics presently has a consensus price target of $63.00, indicating a potential downside of 3.79%. Pliant Therapeutics has a consensus price target of $3.00, indicating a potential upside of 365.12%. Given Pliant Therapeutics’ higher probable upside, analysts clearly believe Pliant Therapeutics is more favorable than TG Therapeutics.
Institutional & Insider Ownership
58.6% of TG Therapeutics shares are owned by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are owned by institutional investors. 8.9% of TG Therapeutics shares are owned by insiders. Comparatively, 8.7% of Pliant Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
TG Therapeutics beats Pliant Therapeutics on 12 of the 15 factors compared between the two stocks.
About TG Therapeutics
TG Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for B-cell diseases, including autoimmune disorders and blood cancers. Its research has centered on therapies that target B cells, a type of immune cell involved in these conditions. The company’s marketed product, BRIUMVI (ublituximab-xiiy), is an anti-CD20 monoclonal antibody approved in the United States to treat adults with relapsing forms of multiple sclerosis. TG Therapeutics also has investigated other drug candidates and combinations for immune-related and hematologic diseases.
About Pliant Therapeutics
Pliant Therapeutics is a biopharmaceutical company focused on developing medicines for fibrotic diseases, in which excess scar tissue can impair the function of organs. The company’s research centers on integrins, proteins involved in processes such as tissue repair and fibrosis. Its investigational programs have included bexotegrast, an oral drug designed to inhibit the αvβ6 and αvβ1 integrins and studied for conditions including idiopathic pulmonary fibrosis. Pliant has also pursued other drug candidates targeting fibrotic disease pathways.
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
